Ligand Pharmaceuticals Incorporated - Common Stock (LGND)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Jul 29, 2026Investment Snapshot
- Trading 387% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 4/9 — moderate financial health
- ROE of 6.7% — below-average profitability
- Revenue growing at 60% annually
Ligand Pharmaceuticals Incorporated - Common Stock (LGND) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $5.9 billion . Key value metrics: P/E ratio 89.5, P/B ratio 5.95, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Ligand Pharmaceuticals Incorporated - Common Stock — Fundamental Analysis Summary
Ligand Pharmaceuticals Incorporated - Common Stock (LGND) is currently trading 387% above its Graham Number of $60.87, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 89.5x.
On financial health, LGND shows a moderate Piotroski F-Score of 4/9, and modest return on equity of 6.7% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.53.
StockPik's composite Value Score for LGND is 35/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
LGND shows revenue growing at 60% year-over-year, with earnings growing at 3,187%.